Ching‐Kai Shen

422 total citations
8 papers, 312 citations indexed

About

Ching‐Kai Shen is a scholar working on Immunology, Molecular Biology and Genetics. According to data from OpenAlex, Ching‐Kai Shen has authored 8 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Immunology, 2 papers in Molecular Biology and 2 papers in Genetics. Recurrent topics in Ching‐Kai Shen's work include Immune cells in cancer (3 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Tryptophan and brain disorders (2 papers). Ching‐Kai Shen is often cited by papers focused on Immune cells in cancer (3 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Tryptophan and brain disorders (2 papers). Ching‐Kai Shen collaborates with scholars based in Taiwan and United States. Ching‐Kai Shen's co-authors include Dah‐Yuu Lu, Cheng‐Fang Tsai, Wei‐Lan Yeh, Liang‐Yo Yang, Guan‐Wei Chen, Jia-Hong Chen, Yen-Chang Chen, Bor‐Ren Huang, Yu‐Shu Liu and Sheng‐Wei Lai and has published in prestigious journals such as International Journal of Molecular Sciences, Nutrients and European Journal of Pharmacology.

In The Last Decade

Ching‐Kai Shen

8 papers receiving 310 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ching‐Kai Shen Taiwan 7 109 107 55 32 31 8 312
Edina Pandur Hungary 14 133 1.2× 69 0.6× 46 0.8× 28 0.9× 36 1.2× 28 478
Yunsha Zhang China 10 162 1.5× 97 0.9× 125 2.3× 24 0.8× 10 0.3× 22 394
Ruixia Deng Hong Kong 11 181 1.7× 37 0.3× 47 0.9× 54 1.7× 31 1.0× 18 501
Ramóna Pap Hungary 10 92 0.8× 108 1.0× 36 0.7× 31 1.0× 13 0.4× 20 356
Lin‐Sheng Yu China 11 156 1.4× 48 0.4× 35 0.6× 16 0.5× 15 0.5× 22 354
Aodi He China 12 133 1.2× 50 0.5× 44 0.8× 62 1.9× 11 0.4× 21 356
Maojuan Guo China 14 231 2.1× 85 0.8× 26 0.5× 21 0.7× 22 0.7× 23 433
Anta Ngkelo United Kingdom 7 172 1.6× 136 1.3× 34 0.6× 35 1.1× 12 0.4× 8 419

Countries citing papers authored by Ching‐Kai Shen

Since Specialization
Citations

This map shows the geographic impact of Ching‐Kai Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ching‐Kai Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ching‐Kai Shen more than expected).

Fields of papers citing papers by Ching‐Kai Shen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ching‐Kai Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ching‐Kai Shen. The network helps show where Ching‐Kai Shen may publish in the future.

Co-authorship network of co-authors of Ching‐Kai Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Ching‐Kai Shen. A scholar is included among the top collaborators of Ching‐Kai Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ching‐Kai Shen. Ching‐Kai Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Huang, Bor‐Ren, Chingju Lin, Chao‐Wei Chen, et al.. (2024). LPS priming-induced immune tolerance mitigates LPS-stimulated microglial activation and social avoidance behaviors in mice. Journal of Pharmacological Sciences. 154(4). 225–235. 5 indexed citations
2.
Shen, Ching‐Kai, Bor‐Ren Huang, Liang‐Yo Yang, et al.. (2023). Inhibitory Effects of Urolithins, Bioactive Gut Metabolites from Natural Polyphenols, against Glioblastoma Progression. Nutrients. 15(23). 4854–4854. 9 indexed citations
3.
Shen, Ching‐Kai, Bor‐Ren Huang, Liang‐Yo Yang, et al.. (2023). Bradykinin B1 Receptor Affects Tumor-Associated Macrophage Activity and Glioblastoma Progression. Antioxidants. 12(8). 1533–1533. 7 indexed citations
4.
Tsai, Cheng‐Fang, Guan‐Wei Chen, Yen-Chang Chen, et al.. (2021). Regulatory Effects of Quercetin on M1/M2 Macrophage Polarization and Oxidative/Antioxidative Balance. Nutrients. 14(1). 67–67. 198 indexed citations
5.
Liu, Yu‐Shu, Bor‐Ren Huang, Chingju Lin, et al.. (2021). Paliperidone Inhibits Glioblastoma Growth in Mouse Brain Tumor Model and Reduces PD-L1 Expression. Cancers. 13(17). 4357–4357. 17 indexed citations
6.
Shen, Ching‐Kai, Bor‐Ren Huang, Wei‐Lan Yeh, et al.. (2021). Regulatory effects of IL-1β in the interaction of GBM and tumor-associated monocyte through VCAM-1 and ICAM-1. European Journal of Pharmacology. 905. 174216–174216. 40 indexed citations
7.
Lin, Chingju, Sheng‐Wei Lai, Ching‐Kai Shen, et al.. (2021). Fenofibrate inhibits hypoxia‐inducible factor‐1 alpha and carbonic anhydrase expression through activation of AMP‐activated protein kinase/HO‐1/Sirt1 pathway in glioblastoma cells. Environmental Toxicology. 36(12). 2551–2561. 15 indexed citations
8.
Huang, Bor‐Ren, Yu‐Shu Liu, Sheng‐Wei Lai, et al.. (2020). CAIX Regulates GBM Motility and TAM Adhesion and Polarization through EGFR/STAT3 under Hypoxic Conditions. International Journal of Molecular Sciences. 21(16). 5838–5838. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026